#EULAR OP0072: SMILE: Self-Management Individualised Learning Environment for RA 😀5 modules, with 3-4 more planned in 2022 😀Learning objectives 😀Plan to target resources to questionnaire @RheumNow

Behcet disease: RCT Topical Tacrolimus for mouth ulcers in 40+pts ↘️VAS 2 wks & 3mo ↘️ Number of ulcers ↘️ Ulcer size and duration ↘️ Ulcer severity score #OP0046 #EULAR2022 @RheumNow

SELECT-AXIS 2: RCT UPA 15 mgQD vs. PBO in NRAxSpA as expected: ↘️disease activity ↘️pain and function ↘️QoL at 14 wks no new safety alerts https://t.co/2efpx7Mi6i

AxSpA and AxPsA 2 sides of the same coin or 2 different diseases? Divergent IL-23i efficacy data seem to suggest the latest. German GESPIC AxPsA cohort: *More frequently 🚺 *Less frequently B27+ *20% isolated Ax involvement @Rheumnow OP0026 #EULAR2022 https://t.co/FZP9nEyG7J

Long-term canakinumab data in FMF from RELIANCE registry. 63% in remission at month 24. @RheumNow #EULAR2022 OP0042 https://t.co/mEIoAszmZq https://t.co/IvR1cSG4Aq

• EULAR Abstract Archive

Can be challenging to identify early/impending MAS in AoSD. Ruscitti et al propose a model based on systemic score, ferritin, IFN-γ, and IL-10 with AUC 0.99, sensitivity 100% specificity 95% @RheumNow #EULAR2022 OP0044 https://t.co/bbWkdGCnHP

• EULAR Abstract Archive

More from the VITAL study Dr Costenbader @karen_kc123 et al. 5 year supplementation followed 2 year follow up. Vit D 2000iu ⬇️incident autoimmune disease 21%. RA, PMR, psoriasis trend towards reduction. No effect omega-3 @RheumNow #EULAR2022 OP0038 https://t.co/kbKqDhtN9z https://t.co/HcFXbweEPm

• EULAR Abstract Archive

Severe heme relapses are common in #SLE pts w/prior severe heme episodes: ATTIKON SLE cohort 800 pts 👉13% w/severe heme dz: TMA, MAS, plt < 30K, hemolysis hgb < 8 👉heme issues preceded SLE dx in 1/3 of pts 👉>50% pts had severe heme flare 👉0 deaths #EULAR2022 @rheumnow POS0116

Low rates of hypersensitivity reactions (HSR) to #anifrolumab Pooled data MUSE & TULIP-1/-2 w/1100 pts: 👉1 anaphylaxis (0.15%) 👉12 HSR (3%) 👉43 infusion reaction (9%): N/V/headache 👉most easily treatable w/antihistamine, GCs, acetaminophen #EULAR2022 POS0708 @rheumnow

Another study that shows longterm exposure to pollutants can increased risk for autoimmune/immune mediated inflammatory diseases #EULAR2022 OP0071 @rheumnow #SaveEarth https://t.co/hMFJfEOcV1

Once we add adalimumab in MTX-IR RA, can we dial down MTX & still keep control? New data - now in East Asian pts (with already low MTX) says often yes, without ⬆️ADAb. Obviously RA control 1st/2nd/3rd, but prob doesn’t have to be MTX 20 forever in everyone #EULAR2022 @RheumNow https://t.co/aZ0bsgY7dC

It's not a museum. It's the new, look, all electronic poster sessions. Rows & rows of 42 inch touch screen monitors on the wall. You can interact with these online monitors, but I was unable to connect to Netflix. #EULAR22 https://t.co/yYb0HaMWHJ

Prof Pickering explained interpretation of Low Complement level and its association with Complement Pathways and Diseases #EULAR2022 @RheumNow 💠 ⬇️C4, normal/⬇️C3: Classical 💠 ⬇️C3, normal C4: Alternative https://t.co/fBKKNzWnNW

We are back!!! #EULAR22 https://t.co/njNKyVqu5u